April 2026 Research Update

This month brought an early, laboratory-based signal that it may be possible to directly restore CDKL5 in patient-derived cells and see related nerve cell problems improve. The work does not show what will happen in people, but it helps connect a specific type of gene correction to measurable changes in CDKL5 and in how neurons function in a controlled setting. [1]

In a patient-derived cell model of CDKL5 deficiency disorder, researchers used base editing (a gene editing approach) and reported that CDKL5 expression was restored. They also reported a rescue of neuronal deficits in that model, meaning the nerve cell features they were tracking moved back toward a more typical pattern after editing. More specifically, the edited neurons showed restored CDKL5 protein and CDKL5-dependent signaling, along with normalization of cell-shape and gene-expression abnormalities toward the matched control cells. [1]

For families, this study mainly adds to longer-term research aimed at treatments that address the underlying CDKL5 gene problem rather than only symptoms. Because the results are from patient-derived cells in the lab, they do not tell us whether base editing would be safe or effective in a child or adult with CDKL5 deficiency disorder. What it does clarify is that restoring CDKL5 in a human cell model can line up with improvements in neuron-related measurements, which is an encouraging step that would still need much more testing before it could be considered for real-world care. [1]

Another line of research this month focused on basic CDKL5 biology: how the CDKL5 protein is chemically modified inside cells and how that changes during neuron-like development. The main message is that CDKL5 appears to be tightly controlled by a balance of cellular "on" and "off" switches, and this balance can shift with signals that push cells toward a more neuron-like state. This is not a treatment study, but it helps map the control systems that might matter for understanding CDKL5 function. [2]

In cultured cell lines, CDKL5 was reported to be highly phosphorylated (a common chemical tag cells use to control protein behavior), and it was mainly found in the cytoplasm in one of the models. During a process where aggregates formed in cells, CDKL5 gradually became less phosphorylated, and retinoic acid (a signal used to drive neuronal differentiation in the lab) suppressed that dephosphorylation. The study also reported that PP2A partly contributed to removing phosphorylation, while multiple PKC enzymes contributed to adding phosphorylation. [2]

For patients and caregivers, this work is best viewed as early-stage groundwork rather than something that changes care now. It helps clarify that CDKL5 is not just "present or absent" in cells; its activity may also depend on how it is modified and which cellular control proteins (like PKC and PP2A) are active. What remains uncertain is how these lab findings relate to the brain in people with CDKL5 deficiency disorder, and whether adjusting these control pathways could ever translate into a safe therapy. [2]